Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

1.690 +0.030 (+1.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akebia Therapeutics

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
Exposures Product Safety
Akebia Therapeutics Inc. (NASDAQ: AKBA) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via TheNewswire.com
Exposures Product Safety
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/20/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc.. 
Via SBWire
AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:AKBA Investor Notice: Deadline on May 13, 2022 in Lawsuit Against Akebia Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- The Shareholders Foundation announced that a deadline is coming up on May 13, 2022 in the lawsuit filed for certain investors of Akebia Therapeutics, Inc.... 
Via SBWire
AKBA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AKBA INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia... 
Via SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
From The Rosen Law Firm, P.A.
Via Business Wire
AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
From Rosen Law Firm
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger
From Robbins LLP
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced... 
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.